SAB Biotherapeutics
SABS----
Q1 FY2026 Earnings
Financial report interval: 2025.12.31 - 2026.03.31
Preview: SAB Biotherapeutics(SABS) predict that the EBIT is -20 M (-85.64%), Miss estimate;the EPS is -0.35 (+37.5%), Miss estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
Revenue
TBA--
0.00B--
----
EBITMiss expectations
-0.02B85.64%
-0.02B43.25%
-0.00B42.39%
EPSMiss expectations
-0.3537.50%
-0.20862.86%
-0.142025.36%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf